| P2093 | author name string | Giedre Krenciute | |
| | Christopher T Petersen | |
| P2860 | cites work | Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins | Q24294612 |
| | IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells | Q24621753 |
| | T cell activation | Q24658051 |
| | The past, present and future of immunotherapy against tumor | Q26799896 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 |
| | Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors | Q30711622 |
| | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | Q33561644 |
| | CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells | Q33671867 |
| | In vivo discovery of immunotherapy targets in the tumour microenvironment | Q33736396 |
| | Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 | Q33749635 |
| | Improved survival time trends for glioblastoma using the SEER 17 population-based registries | Q33828439 |
| | Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits | Q34046041 |
| | Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. | Q55358019 |
| | Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. | Q55378779 |
| | Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. | Q55456560 |
| | Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor | Q56568324 |
| | CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells | Q56890079 |
| | Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients | Q56932510 |
| | CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges | Q57291659 |
| | Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas | Q57300937 |
| | Reprogramming human T cell function and specificity with non-viral genome targeting | Q57555848 |
| | Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells | Q58889356 |
| | Chimeric Antigen Receptor Therapy | Q89419402 |
| | Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors | Q90929525 |
| | Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function | Q91068331 |
| | Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition | Q34047618 |
| | Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. | Q34487189 |
| | IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. | Q35506724 |
| | Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning | Q35986612 |
| | Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases | Q36941051 |
| | Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition | Q37137924 |
| | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape | Q37137932 |
| | Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation | Q37183578 |
| | The role of microglia in central nervous system immunity and glioma immunology | Q37206898 |
| | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 |
| | Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells | Q37474007 |
| | The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. | Q38267385 |
| | TRUCKs: the fourth generation of CARs | Q38488557 |
| | Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. | Q38837469 |
| | Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. | Q38976993 |
| | T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints | Q39037803 |
| | The movers and shapers in immune privilege of the CNS. | Q39090554 |
| | Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities | Q39264898 |
| | Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells | Q40318331 |
| | Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. | Q40323802 |
| | Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 |
| | PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients | Q42354900 |
| | Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma | Q42696122 |
| | Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants | Q45868285 |
| | Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. | Q45870666 |
| | Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. | Q45871070 |
| | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. | Q45946525 |
| | Current trends in mouse models of glioblastoma. | Q47169542 |
| | Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications | Q47561397 |
| | Identification of essential genes for cancer immunotherapy. | Q47736099 |
| | High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model | Q47947865 |
| | Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. | Q48648729 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| | cell engineering | Q10472873 |
| P304 | page(s) | 69 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma | |
| P478 | volume | 9 | |